



1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Daniel Caput et al.

Serial No.: 09/077,817

Filed: September 14, 1998

Group Art Unit: 1646

Examiner: Basi, N.

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to:

Assistant Commissioner for Patents,
Washington, DC 20231.

Paula L. Dickey
Name

September 26, 2001
Date

24/D
199
10/3/01

For: Purified Polypeptides Having IL-13 Receptor Activity

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT

RECEIVED
OCT 02 2001
TECH CENTER 1600/2900

In response to the Office Communication mailed September 13, 2001 (Paper No. 23) setting a one-month period for response, please amend the above-identified application as follows:

In the Specification

Please delete the partial duplicate of page 46 which contains the text of lines 1-21 beginning with "or its complementary strand." and ending with "used in gene therapy".

Please delete in its entirety the unnumbered page immediate following page 49 beginning with "SANOFI" and ending with "No. 2."

At page 1, immediate preceding line 1, add the following title:

--PURIFIED POLYPEPTIDES HAVING IL-13 RECEPTOR ACTIVITY--

Following the claims add the abstract page submitted herewith.